» Articles » PMID: 32905906

Molecular Mechanisms of FasL-mediated 'reverse-signaling'

Overview
Journal Mol Immunol
Date 2020 Sep 9
PMID 32905906
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Effector lymphocytes, including NK and T cells, express FasL. Expression of Fas, the receptor for FasL in tumor cells, renders them susceptible to NK and T cell-mediated killing. The functional relevance of FasL in initiating death signals in tumor cells is well-characterized. However, the cytoplasmic interacting partners and the potential signaling pathways downstream of FasL are far from fully defined. FasL possesses an 81 amino acid long cytoplasmic tail with multiple unique recruitment motifs. We predict multiple interdependent signaling complexes form the core of the 'reverse signaling' downstream of FasL. A direct interaction between the proline-rich domain of FasL and the SH3 domain of PI(3)K-p85α initiates the first pathway. This cascade helps FasL to link to PLC-γ2 via PIP or the Akt-dependent activation of mTOR complexes. Independently, a GRB2/GADs-binding PXXP cytoplasmic motif of FasL can initiate a Ras-GTP-dependent PAK1→C-Raf→MEK1/2→ERK1/2 activation. FasL can recruit Fyn via the proline-rich domain leading to the recruitment of ADAP. Through its ability to directly interact with Carma1 and TAK1, ADAP initiates the formation of the Carma1/Bcl10/Malt1-based CBM signalosome that is primarily responsible for inflammatory cytokine production. Here, we explore the conserved cytoplasmic domains of FasL, the potential signaling molecules that interact, and the functional downstream consequences within the effector lymphocytes to define the FasL-mediated 'reverse signaling'.

Citing Articles

A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4 T helper cell signaling, differentiation and epigenetic remodeling.

Golec D, Gazzinelli-Guimaraes P, Chauss D, Nagashima H, Yu K, Hill T bioRxiv. 2025; .

PMID: 39803425 PMC: 11722529. DOI: 10.1101/2024.10.28.620691.


Fyn, an important molecule in the brain, is a potential therapeutic target for brain tumours.

Xu C, Tang Y, Lu X, Chen R Front Pharmacol. 2024; 15:1485919.

PMID: 39697541 PMC: 11652172. DOI: 10.3389/fphar.2024.1485919.


Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.

Oli A, Adejumo S, Rowaiye A, Ogidigo J, Hampton-Marcell J, Ibeanu G J Immunol Res. 2024; 2024:8481761.

PMID: 39483536 PMC: 11527548. DOI: 10.1155/2024/8481761.


The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma.

Li S, Dai W, Kam N, Zhang J, Lee V, Ren X Cancers (Basel). 2024; 16(7).

PMID: 38610990 PMC: 11011204. DOI: 10.3390/cancers16071312.


Fas ligand regulate nerve injury and repair by affecting AKT, β-catenin, and NF-κB pathways.

Zhou Y, Yao Y, Feng Y, Qiu Z, Luo S, Shi X IBRO Neurosci Rep. 2024; 16:455-467.

PMID: 38544794 PMC: 10966190. DOI: 10.1016/j.ibneur.2024.02.008.


References
1.
Fruman D, Snapper S, Yballe C, Davidson L, Yu J, Alt F . Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 1999; 283(5400):393-7. DOI: 10.1126/science.283.5400.393. View

2.
Shrestha B, Diamond M . Fas ligand interactions contribute to CD8+ T-cell-mediated control of West Nile virus infection in the central nervous system. J Virol. 2007; 81(21):11749-57. PMC: 2168805. DOI: 10.1128/JVI.01136-07. View

3.
Dibble C, Elis W, Menon S, Qin W, Klekota J, Asara J . TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell. 2012; 47(4):535-46. PMC: 3693578. DOI: 10.1016/j.molcel.2012.06.009. View

4.
Luckerath K, Kirkin V, Melzer I, Thalheimer F, Siele D, Milani W . Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. Blood. 2010; 117(2):519-29. DOI: 10.1182/blood-2010-07-292722. View

5.
Nagata S, Suda T . Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995; 16(1):39-43. DOI: 10.1016/0167-5699(95)80069-7. View